Literature DB >> 31303996

Controlling cellular distribution of drugs with permeability modifying moieties.

Paul L Richardson1, Violeta L Marin1, Stormy L Koeniger1, Aleksandra Baranczak1, Julie L Wilsbacher2, Peter J Kovar2, Patricia E Bacon-Trusk2, Min Cheng2, Todd A Hopkins2, Sandra T Haman2, Anil Vasudevan1.   

Abstract

Phenotypic screening provides compounds with very limited target cellular localization data. In order to select the most appropriate target identification methods, determining if a compound acts at the cell-surface or intracellularly can be very valuable. In addition, controlling cell-permeability of targeted therapeutics such as antibody-drug conjugates (ADCs) and targeted nanoparticle formulations can reduce toxicity from extracellular release of drug in undesired tissues or direct activity in bystander cells. By incorporating highly polar, anionic moieties via short polyethylene glycol linkers into compounds with known intracellular, and cell-surface targets, we have been able to correlate the cellular activity of compounds with their subcellular site of action. For compounds with nuclear (Brd, PARP) or cytosolic (dasatinib, NAMPT) targets, addition of the permeability modifying group (small sulfonic acid, polycarboxylic acid, or a polysulfonated fluorescent dye) results in near complete loss of biological activity in cell-based assays. For cell-surface targets (H3, 5HT1A, β2AR) significant activity was maintained for all conjugates, but the results were more nuanced in that the modifiers impacted binding/activity of the resulting conjugates. Taken together, these results demonstrate that small anionic compounds can be used to control cell-permeability independent of on-target activity and should find utility in guiding target deconvolution studies and controlling drug distribution of targeted therapeutics.

Entities:  

Year:  2019        PMID: 31303996      PMCID: PMC6595965          DOI: 10.1039/c8md00412a

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  41 in total

1.  A quantitative analysis of kinase inhibitor selectivity.

Authors:  Mazen W Karaman; Sanna Herrgard; Daniel K Treiber; Paul Gallant; Corey E Atteridge; Brian T Campbell; Katrina W Chan; Pietro Ciceri; Mindy I Davis; Philip T Edeen; Raffaella Faraoni; Mark Floyd; Jeremy P Hunt; Daniel J Lockhart; Zdravko V Milanov; Michael J Morrison; Gabriel Pallares; Hitesh K Patel; Stephanie Pritchard; Lisa M Wodicka; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2008-01       Impact factor: 54.908

2.  A small molecule-kinase interaction map for clinical kinase inhibitors.

Authors:  Miles A Fabian; William H Biggs; Daniel K Treiber; Corey E Atteridge; Mihai D Azimioara; Michael G Benedetti; Todd A Carter; Pietro Ciceri; Philip T Edeen; Mark Floyd; Julia M Ford; Margaret Galvin; Jay L Gerlach; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Michael A Insko; Andiliy G Lai; Jean-Michel Lélias; Shamal A Mehta; Zdravko V Milanov; Anne Marie Velasco; Lisa M Wodicka; Hitesh K Patel; Patrick P Zarrinkar; David J Lockhart
Journal:  Nat Biotechnol       Date:  2005-02-13       Impact factor: 54.908

3.  4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

Authors:  Keith A Menear; Claire Adcock; Robert Boulter; Xiao-ling Cockcroft; Louise Copsey; Aaron Cranston; Krystyna J Dillon; Jan Drzewiecki; Sheila Garman; Sylvie Gomez; Hashim Javaid; Frank Kerrigan; Charlotte Knights; Alan Lau; Vincent M Loh; Ian T W Matthews; Stephen Moore; Mark J O'Connor; Graeme C M Smith; Niall M B Martin
Journal:  J Med Chem       Date:  2008-09-19       Impact factor: 7.446

4.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

5.  Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.

Authors:  Giorgio Ottaviani; Sophie Martel; Pierre-Alain Carrupt
Journal:  J Med Chem       Date:  2006-06-29       Impact factor: 7.446

6.  Histamine and its receptors.

Authors:  Mike E Parsons; C Robin Ganellin
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

7.  Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.

Authors:  Darren R Veach; Mohammad Namavari; Nagavarakishore Pillarsetty; Elmer B Santos; Tatiana Beresten-Kochetkov; Caryl Lambek; Blesida J Punzalan; Christophe Antczak; Peter M Smith-Jones; Hakim Djaballah; Bayard Clarkson; Steven M Larson
Journal:  J Med Chem       Date:  2007-10-23       Impact factor: 7.446

8.  Rapid action of estrogens on intracellular calcium oscillations in primate luteinizing hormone-releasing hormone-1 neurons.

Authors:  Hideki Abe; Kim L Keen; Ei Terasawa
Journal:  Endocrinology       Date:  2007-12-13       Impact factor: 4.736

9.  Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.

Authors:  Robert J Altenbach; Huaqing Liu; Patricia N Banfor; Kaitlin E Browman; Gerard B Fox; Ryan M Fryer; Victoria A Komater; Kathleen M Krueger; Kennan Marsh; Thomas R Miller; Jia Bao Pan; Liping Pan; Minghua Sun; Christine Thiffault; Jill Wetter; Chen Zhao; Deliang Zhou; Timothy A Esbenshade; Arthur A Hancock; Marlon D Cowart
Journal:  J Med Chem       Date:  2007-10-06       Impact factor: 7.446

10.  Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage.

Authors:  Ubaldina Galli; Emanuela Ercolano; Lorenzo Carraro; Cintia R Blasi Roman; Giovanni Sorba; Pier Luigi Canonico; Armando A Genazzani; Gian Cesare Tron; Richard A Billington
Journal:  ChemMedChem       Date:  2008-05       Impact factor: 3.466

View more
  1 in total

1.  BET bromodomain inhibitors regulate keratinocyte plasticity.

Authors:  Gabi Schutzius; Christian Kolter; Sebastian Bergling; Federico Tortelli; Florian Fuchs; Steffen Renner; Vito Guagnano; Simona Cotesta; Heinrich Rueeger; Michael Faller; Laure Bouchez; Adrian Salathe; Florian Nigsch; Shola M Richards; Malvina Louis; Viktoria Gruber; Alexandra Aebi; Jonathan Turner; Frederic Grandjean; Jun Li; Chris Dimitri; Jason R Thomas; Markus Schirle; Jutta Blank; Peter Drueckes; Andrea Vaupel; Ralph Tiedt; Paul W Manley; Julia Klopp; Rene Hemmig; Florence Zink; Nelly Leroy; Walter Carbone; Guglielmo Roma; Caroline Gubser Keller; Natalie Dales; Armin Beyerbach; Alfred Zimmerlin; Debora Bonenfant; Remi Terranova; Amy Berwick; Sukhdeep Sahambi; Aimee Reynolds; Lori L Jennings; Heinz Ruffner; Peter Tarsa; Tewis Bouwmeester; Vickie Driver; Mathias Frederiksen; Felix Lohmann; Susan Kirkland
Journal:  Nat Chem Biol       Date:  2021-01-18       Impact factor: 15.040

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.